CRISPR Researchers Engineer More Efficient Cas12a Variants for Genetic, Epigenetic, Base Editing

Feb 11, 2019

|

NEW YORK (GenomeWeb) – In a study published today in Nature Biotechnology, researchers in Keith Joung's lab at Massachusetts General Hospital described their efforts to engineer enhanced variants of the Cas12a nuclease that can target a wider range of protospacer adjacent motifs (PAM), have enhanced editing activity, and have reduced off-target effects.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

European Regulators Begin Review of Sputnik V

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Irish Funding Agency Seeks Boost

Science reports that Science Foundation Ireland is seeking annual budget increases.

Lower Fees Sought

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

Featured White Papers

Compatibility of Liquid Biopsy Assays on Multiple Sequencing Platforms

CAS-CLOVER The clean alternative to CRISPR/Cas9 for gene editing in the drug discovery and development industry

Mar

09

Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams.

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

24

Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Apr

23

Featured Webinar

Advances in Single-Cell Proteomics: Building a Complete Picture of Cellular Identity

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function.

Menu

CRISPR Researchers Engineer More Efficient Cas12a Variants for Genetic, Epigenetic, Base Editing

To read the full story....

Breaking News

C2i Genomics Acquires Sequencing Lab QNA Dx

Genetic Technologies Inks US Commercialization Deal for COVID-19 Risk Test With Infinity Biologix

Waters Enters $500M Senior Notes Private Placement

Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

Agilent Prices $850M Senior Notes Offering

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

The Scan

European Regulators Begin Review of Sputnik V

Irish Funding Agency Seeks Boost

Lower Fees Sought

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

Featured White Papers

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Advances in Single-Cell Proteomics: Building a Complete Picture of Cellular Identity

What's Popular?

ERS Genomics Licenses CRISPR Patents to Otsuka Pharmaceutical

Sponsorships